Common diabetes drug may lower dementia risk, study shows
Common diabetes drug may lower dementia risk, study shows
NEW DELHI: A common diabetes drug could prevent dementia, with a longer treatment being related with more benefits, a study on Korean population has suggested.
In over two lakh adults aged 40-69 years and having type 2 diabetes, researchers found a 35 per cent reduced risk of dementia associated with taking SGLT-2 inhibitors compared with DPP-4 inhibitors, also known as gliptins.
Further, treatment with SGLT-2 drugs over a longer duration was found to have more pronounced effects -- a 48 per cent reduced risk of dementia for more than two years of treatment. Examples of SGLT-2 drugs available in India include remogliflozin and dapagliflozin, while those of DPP-4 drugs are sitagliptin, vildagliptin, and teneligliptin.
